Sartorius launched a new genetically engineered CHO host cell line that the company says improves productivity and efficiency. The team leveraged proteomic profiling and targeted genome editing to generate the rational-designed host cell line, according to a Sartorius spokesperson.
Sartorius tested the new CHO host cell line across multiple cell line development (CLD) campaigns from DNA to lead clone expressing a range of different therapeutic proteins. At five-liter bioreactor scale, the new host demonstrated up to a two-fold increase in expression titers, and up to a three-fold increase in productivity when directly compared against lead clones derived from the original wild-type CHO host in traditional fed-batch processes, reports the company, adding that the cell line enabled this productivity increase while maintaining high product quality. This performance was shown to be consistent across IgG1, IgG4, Fc-fusion, and bispecifics.
In intensified bioprocessing, the engineered host also supports higher titers and long culture duration in continuous perfusion, notes Oscar Reif, head of corporate research and CTO. For a selected clone expressing a monoclonal antibody, Sartorius observed a two-fold increase in titer per day along with maintained high cell density and viability (more than 80 percent) for a culture duration of up to 28 days.
The cell line is designed for reliability, with more than 90 percent of evaluated clones demonstrating continuous protein expression and maintaining low gene copy number over more than 70 generations, ultimately supporting long-term manufacturing consistency along with regulatory confidence, points out Reif.
“To the best of our knowledge, this is the first engineered CHO host cell line to deliver performance at this exceptional level in the CLD market,” he says.
The post Sartorius Introduces Rationally-Designed CHO Host Cell Line appeared first on GEN – Genetic Engineering and Biotechnology News.
